Weekly Policy Blog: CBSA Supports Biomarker Testing Coverage Bill (HB23-1110)

CBSA is supporting HB23-1110, an important bill introduced in Colorado this year that would require insurance coverage for biomarker testing supported by nationally recognized clinical practice guidelines for diagnosis, treatment, and disease management. Biomarker testing is recognized as the key to unlocking precision medicine. Efforts to pass this biomarker testing bill, sponsored by Representative Dafna Michaelson Jenet, Representative Anthony Hartsook, Senator Kyle Mullica, and Senator Janice Rich, are being spearheaded by the American Cancer Society Cancer Action Network (ACS CAN) following the passage of similar bills in Arizona, Illinois, Louisiana, and Rhode Island. HB23-1110 will be heard in the House Health & Insurance Committee on February 21.

What is Biomarker Testing? 

Biomarker testing is the analysis of a patient’s tissue, blood, or other specimen for the presence of a biomarker which provides insight into the individual’s medical condition and the likelihood that…
Click here to view original post